Medivation Rejects Sanofi’s $9 Billion Bid

The board of US biopharmaceuticals producer Medivation has unanimously rejected French drugmaker Sanofi’s $9.3 billion bid to acquire the company. David Hung, founder, president and CEO of the California-based prostate cancer specialist, said the cash offer, which he termed “opportunistically timed” as the company’s share price has deteriorated over the past several months, “substantially undervalues” the company.

Sanofi had offered to pay $52.50 a share in cash, which it said represented a 50% premium over Medivation’s two-month volume-weighted average. Despite the rejection, the French company indicated it is not prepared to abandon the hoped-for deal.

While Medivation “has chosen not to enter into discussions regarding this value-creating transaction,” Sanofi said it remains committed to the “compelling combination” and added that it is looking forward to “engaging directly with Medivation shareholders.” Sanofi said it is “a disciplined acquirer” and has a strong acquisition track-record.               

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read